Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112577 · ClinicalTrials.gov registry record · Phase 1
Study of REGN3500 and Dupilumab in Patients With Asthma
A Phase 1 study of Asthma, Allergic, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 5
- Study locations
NCT03112577 is a Phase 1 study of Asthma, Allergic that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 32 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT03112577, a Phase 1 study of Asthma, Allergic, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 5
- Study locations
Study Summary
To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with those at screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG REGN3500
- DRUG Fluticasone propionate
Study Locations (5)
Other
- Celerion - Belfast
- Hammersmith Medicine Research - London
- Respiratory Clinical Trials Ltd - London
- The Medicines Evaluation Unit - Manchester
California
- WCCT Global - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2019-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03112577
The ClinicalTrials.gov registry entry for NCT03112577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma, Allergic appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03112577 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT03112577 about?
NCT03112577 is a clinical study titled "Study of REGN3500 and Dupilumab in Patients With Asthma". To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with...
What is the current status of trial NCT03112577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-06-15. Estimated completion is 2019-12-09.
What conditions does trial NCT03112577 study?
This clinical trial studies the following conditions: Asthma, Allergic.
What interventions are being tested in trial NCT03112577?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), REGN3500 (DRUG), Fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT03112577?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03112577 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma, Allergic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.